HNF1A and colorectal carcinoma: Thus, HNF1A was thought to be involved in factors that are more widely related to anticancer drug resistance, and our results showed that HNF1A may be a therapeutic target for patients with CRC to suppress MDR protein activity, resulting in improvements in chemosensitivity.